We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




MRD Assessed by Multiparameter Flow Cytometry in Transplant-Eligible Myeloma

By LabMedica International staff writers
Posted on 05 Jul 2021
Multiple myeloma (MM) treatment has considerably improved in the past 15–20 years. More...
The current paradigm for transplant-eligible newly diagnosed MM (NDMM) patients consists of induction, stem-cell mobilization and autologous stem-cell transplantation (ASCT), followed by consolidation and/or maintenance.

Currently, minimal residual disease (MRD) assessment is the most sensitive tool to measure the depth of response in MM patients. Indeed, among patients achieving a complete response (CR), MRD-positive patients have an inferior progression-free survival (PFS) and overall survival (OS) compared with MRD-negative ones, and a similar outcome to those achieving a partial response (PR).

A large international team working with Hematologists at the University of Torino (Torino, Italy) conducted an MRD correlative study of a MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every six months during maintenance. Transplant-eligible patients aged ≤65 years were enrolled from February 2011 to April 2014 in 172 European centers. A total of 321 patients before lenalidomide maintenance were evaluated for MRD assessment.

Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based multiparameter flow cytometry (MFC) protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. Data were acquired using a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). One of the laboratories (Torino) applied a local panel with minor differences in fluorochromes and antibodies; data were acquired using a Navios flow cytometer and analyzed with Kaluza software (Beckman Coulter, Brea, CA, USA).

The clinical scientists reported that at enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (Hazard Ratio [HR] = 0.39)), 5-year overall survival was 86% versus 69%, respectively (HR = 0.41). MRD negativity was associated with reduced risk of progression or death in all subgroups, including ISS-III (HR = 0.37) and high-risk fluorescence in situ hybridization (FISH) patients (HR = 0.38).

The authors conclude that their study confirms that MRD status by MFC is a strong prognostic factor in NDMM patients receiving intensification with novel agents or high-dose melphalan (HDM). The achievement of MRD negativity in patients with HR-FISH aberrations was associated with a significantly improved survival, underlining the importance of achieving deep responses in this setting. Finally, lenalidomide maintenance further improved the depth of response in standard-risk patients. The study was published on June 3, 2021 in the journal Blood Cancer Journal.

Related Links:
University of Torino
BD Biosciences
Beckman Coulter



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.